19th Apr 2022 08:36
(Alliance News) - GlaxoSmithKline PLC on Tuesday said the US Food & Drug Administration has accepted the company's application for the review of kidney disease drug daprodustat.
The Brentford, England-based pharmaceutical company described the FDA review acceptance as a third major milestone after winning regulatory submission acceptance by the European Medicines Agency and the approval of Duvroq, the same drug under a different name, in Japan.
Daprodustat is used on patients for the treatment of anaemia of chronic kidney disease.
GlaxoSmithKline shares were 0.6% lower at 1,762.60 pence each in London on Tuesday morning.
By Tom Budszus; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline